Healthcare & Pharma M&A
DHA, DOH, and MOHAP diligence, payer concentration, and clinical valuation.
Transactions & Capital
Every transaction is also a risk. We advise on the decision, not only the deal.
We advise on transactions and capital decisions where the quality of judgment determines the outcome. In healthcare and pharma M&A, that judgment turns on regulatory conditions and payer dynamics a generic advisor never surfaces; and what is not surfaced gets priced into the deal later, by the acquirer, after close.
Who engages this
Private equity and family offices acquiring UAE and GCC healthcare assets, founders preparing an exit or fielding an unsolicited approach, boards needing an independent valuation, and growth-stage providers raising equity engage this pillar. Our recommendation to proceed, renegotiate, or walk away is driven by the diligence, not the appetite to close.
The work
What this practice takes on.
0103 0405 06 07 08 09
Buy-Side M&A
Diligence, structuring, and a proceed-or-walk recommendation you can act on.
02Sell-Side M&A
Exit preparation and competitive tension, accountable for enterprise value.
Valuations & Fairness Opinions
Independent DCF, multiples, and royalty relief: the number the asset supports.
Capital Raise Advisory
Investor-grade materials, targeting, and term negotiation.
Family Business Succession
Valuation, governance, and family charter for UAE ownership transition.
CFO-as-a-Service
Senior finance leadership on engagement terms, without the full-time hire.
Financial Modelling
Operating and transaction models built to survive diligence.
Working Capital Advisory
Cash conversion, receivables discipline, and funding headroom.
On a mandate
A GCC family office was acquiring a Dubai clinic group across five DHA-licensed facilities at AED 52 million in revenue. Our diligence found two facility licences carrying unmet conditions, a claims denial rate 340 basis points above benchmark, and one insurer accounting for 67% of revenue, none disclosed in the seller's materials. The findings supported a 14% price adjustment. The deal closed there, with the buyer seeing every exposure it was taking on.
Questions
What clients ask first.
When should we bring you into a deal?
As early as possible, before a letter of intent where we can. The exposures that move price and terms are cheapest to address before you are committed to a counterparty and a timeline.
Why hire a healthcare specialist rather than a general M&A advisor?
UAE healthcare M&A turns on DHA and DOH licence conditions, MOHAP compliance, change-of-control pre-approval timelines, and payer concentration. An advisor who does not know to check these will not find them, and what they miss becomes the acquirer's problem after close.
How long does an independent valuation take?
Ten to fifteen business days for a single entity, twenty to thirty for a group, and twenty-five to thirty-five for a pharmaceutical asset. We will not compress a timeline in a way that compromises the analysis.
If you are weighing an acquisition, an exit, a raise, or a succession, start with a conversation with a principal.